The FDA on Jan. 21 expanded its emergency use authorization for remdesivir to include the drug's use in nonhospitalized patients with mild to moderate COVID-19 who have a high risk of their case becoming severe.
Prior to the agency's announcement via news release, the intravenous treatment had been limited to hospitalized COVID-19 patients.
Remdesivir reduced hospitalizations in COVID-19 patients at high risk for severe progression of the disease, according to data published in December in the New England Journal of Medicine.